<code id='09D3854A08'></code><style id='09D3854A08'></style>
    • <acronym id='09D3854A08'></acronym>
      <center id='09D3854A08'><center id='09D3854A08'><tfoot id='09D3854A08'></tfoot></center><abbr id='09D3854A08'><dir id='09D3854A08'><tfoot id='09D3854A08'></tfoot><noframes id='09D3854A08'>

    • <optgroup id='09D3854A08'><strike id='09D3854A08'><sup id='09D3854A08'></sup></strike><code id='09D3854A08'></code></optgroup>
        1. <b id='09D3854A08'><label id='09D3854A08'><select id='09D3854A08'><dt id='09D3854A08'><span id='09D3854A08'></span></dt></select></label></b><u id='09D3854A08'></u>
          <i id='09D3854A08'><strike id='09D3854A08'><tt id='09D3854A08'><pre id='09D3854A08'></pre></tt></strike></i>

          explore

          explore

          author:fashion    Page View:8638
          Suzanne KreiterGlobe staff

          The state’s celebrated cluster of biotechs has hatched breakthrough medicines for everything from COVID and cystic fibrosis to multiple rare diseases. It has pioneered cutting-edge research in exotic fields like messenger RNA, gene editing, and gene therapies.

          But when it comes to what is arguably the hottest space in drug development today — controlling weight and diabetes for millions of people worldwide — the brainy innovators from Kendall Square have missed out on the booming market, at least so far.

          advertisement

          Instead, the field, which has scientific roots in Massachusetts, is dominated by a pair of global pharma giants: Denmark’s Novo Nordisk, maker of the blockbuster drugs Wegovy and Ozempic, and Indianapolis-based Eli Lilly, which produces the fast-selling Mounjaro.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          Medical records are filled with copy
          Medical records are filled with copy

          AdobeIrecentlytookcareofapatientwhosemedicalrecordsincludedmultiplenotesaboutherpastopen-heartsurger

          read more
          With competition flaring, obesity drug hits goal in liver disease study
          With competition flaring, obesity drug hits goal in liver disease study

          AdobeLONDON—AdrugindevelopmentasaweightlosstreatmentsucceededinaPhase2studyinaseriouslivercondition,

          read more
          Psychedelics group wrestles with new pharma identity
          Psychedelics group wrestles with new pharma identity

          OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

          read more

          For longer

          MarianF.MoratinosforSTATEnticedbytheimmensemarketopenedbyGLP-1weightlossdrugsWegovyandZepbound,ahand